Key Points
- Martine Rothblatt sold 9,500 United Therapeutics shares on April 22 at an average of $576.56 for total proceeds of $5,477,320, reducing her stake by 19% to 40,513 shares valued at about $23.36M.
- United Therapeutics (UTHR) trades near recent highs (opened $572.85; 1‑year high $607.89) with a $25.11B market cap, analysts have raised targets (up to $626) giving a consensus “Moderate Buy” and $601.50 price target, and the company recently beat EPS at $7.70 while revenue rose 7.4% year‑over‑year.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $576.56, for a total value of $5,477,320.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $23,358,175.28. This represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
United Therapeutics Price Performance
Shares of NASDAQ:UTHR opened at $572.85 on Friday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89. The stock's 50-day moving average is $534.64 and its 200 day moving average is $493.24. The company has a market cap of $25.11 billion, a PE ratio of 20.53, a P/E/G ratio of 1.63 and a beta of 0.75.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the prior year, the business earned $6.19 EPS. The business's revenue for the quarter was up 7.4% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have weighed in on UTHR. Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a report on Thursday, March 12th. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Jefferies Financial Group reissued a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. Wells Fargo & Company upped their price objective on United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 31st. Finally, Bank of America upped their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research report on Tuesday, March 31st. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $601.50.
Check Out Our Latest Research Report on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company's stock valued at $127,000 after buying an additional 70 shares during the last quarter. Jump Financial LLC purchased a new stake in United Therapeutics during the 2nd quarter valued at $277,000. Cerity Partners LLC raised its stake in United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company's stock valued at $3,691,000 after buying an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia raised its stake in United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company's stock valued at $468,000 after buying an additional 105 shares during the last quarter. 94.08% of the stock is owned by institutional investors.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
